Genitourinary Cancer

DNA from circulating tumors in patients with metastatic castraction-resistant prostate cancer (mCRPC) could assist in personalizing treatment.

A recent study presented at the 2017 Genitourinary Cancers Symposium found that use of antibiotics could damper the efficacy of checkpoint inhibitors, potentially due to the relationship between gut microbiota and antibiotics.

Some patients with metastatic rena cell carcinoma (mRCC) exhibited sustained responses even up to 6 months of being off the immunotherapy treatment.

For patients with recurrent prostate cancer, adding hormonal therapy to post-surgical radiation treatment significantly improves survival, according to a recent study.

The FDA has granted approval for nivolumab (Opdivo) in the treatment of urothelial carcinoma.

Genitourinary cancer expert discusses autoimmune-related adverse events in patients with renal cell carcinoma (RCC).

The antidiabetic agent, pioglitazone, may possibly increase the risk of bladder cancer, according to the FDA.

A recent study looked at the role that patients' stress and anxiety plays in deciding on treatment for patients with prostate cancer.

Expert Michael Morris, MD, discusses the current and future role of radium-223 dichloride in treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

Longer intervals between zoledronic acid doses for patients with bone metastases did not result in an increased risk of skeletal-related events (SREs).

Tanya Dorff, MD, explains the developments of chemotherapy in firstline treatment for hormone-sensitive metastatic prostate cancer as well as personalized treatment in this population.

Dr. Clayton Lau, a prostate cancer expert, discusses the options for patients with early-stage prostate cancer and the importance of staying educated on this disease.

A recent study found an increased risk of dementia for patients with prostate cancer being treated with ADT, and those patients with the highest risk had been treated with ADT for the longest period of time.

Celestia Higao, MD, talks about the difficulty of discussing sexual health, particularly with male patients.

Deborah Watkins Bruner, RN, PhD, FAAN, discusses the results of a trial comparing quality of life after conventional radiotherapy and after a hypofractionated schedule for men at low-risk for prostate cancer.

Use of PSA tests between 2010 and 2012 at University of Texas Southwestern Medical Center did not significantly change despite the 2012 USPSTF recommendation against PSA screenings.

When treating patients with prostate cancer in survivorship care, Dan Spratt underscores the importance of being aware of potential mental health issues.

For men with positive needle biopsy for prostate cancer, active surveillance (AS) did not negatively impact their quality-of-life compared with men who had a negative prostate needle biopsy.

Most people don't know much about kidney cancer at the time of their diagnosis. The Kidney Cancer Association wants to change that.

Immunotherapy is changing the cancer treatment game as therapies continue to be approved for more and more tumor types. This creates more responsibilities for oncology nurses.

Educate, engage and energize — those are the three main verbs and goals of the Bladder Cancer Advocacy Network’s (BCAN) first ever leadership summit.

Despite obesity as a risk factor for clear cell RCC, a high BMI is a prognostic factor for improved survival in patients with metastatic RCC.

Patients undergoing Androgen-deprivation therapy (ADT) for prostate cancer may be at risk of significant psychological effects.

Matthew Galsky, MD, medical oncologist, Icahn School of Medicine at Mount Sinai, discusses treating different subsets of bladder cancer.